Skip to main content
Fig. 2 | Advances in Rheumatology

Fig. 2

From: Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab

Fig. 2

Proportion of Patients Who Achieved ACR50 Response and DAS28-ESR Remission at Week 24 by Study and Treatment Arm. ACR50, 50% improvement per the American College of Rheumatology; DAS28-ESR, Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; mono, monotherapy; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; TCZ, tocilizumab

Back to article page

Advances in Rheumatology

ISSN: 2523-3106